Cedara results boom as new CFO named

Article

On the financial ropes less than two years ago, Cedara Software is fighting back. The company achieved a 50% boost in revenues in the three months ended March 31 to $13.5 million compared with $9 million in the third quarter of 2003. Net income for the

On the financial ropes less than two years ago, Cedara Software is fighting back. The company achieved a 50% boost in revenues in the three months ended March 31 to $13.5 million compared with $9 million in the third quarter of 2003. Net income for the quarter was $5.1 million, compared with a net loss of $1.6 million in 3Q the previous year. Contributing heavily to the company's improved financial picture were three major agreements Cedara struck with OEMs. Revenues from one of these were recognized in the recent third quarter. Substantial revenues from the other two are likely to be recognized next quarter. In reporting the financial results, Cedara announced the appointment of Brian Pedlar as chief financial officer. He previously served as Cedara's director of finance and administration.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.